HOLX Stock Recent News
HOLX LATEST HEADLINES
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentations at Upcoming Investor Conferences.
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Women's health device maker, Hologic HOLX, slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10 billion remained the same as stated during the February earnings call, reflecting the $100 million cut from the initial guidance.
Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
HOLX delivers earnings and revenue beat in the second quarter of fiscal 2025 amid macroeconomic turbulence.
Hologic, Inc. (NASDAQ:HOLX ) Q2 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Mike Watts - Corporate VP, IR Steve MacMillan - Chairman, President & CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Anthony Petrone - Mizuho Group Lu Li - UBS Casey Woodring - JP Morgan Conor McNamara - RBC Capital Andrew Cooper - Raymond James Mason Carrico - Stephens Operator Good afternoon, and welcome to Hologic's Second Quarter Fiscal 2025 Earnings Conference Call. My name is Rachel, and I'm your operator for today's call.
Medical equipment maker Hologic lowered its fiscal 2025 profit forecast, citing uncertainty around the tariffs imposed by U.S. President Donald Trump's administration, sending the company's shares down 3% after the bell on Thursday.
While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.03 per share a year ago.